Antonio Gonzalez Martín, MD, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.
AntonioGonzález Martín, MD, co-director, Department of Medical Oncology,ClínicaUniversidad de Navarra, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib (Zejula) versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.
Two analyses were performed on these patients in the PRIMA trial, and the primary end point of this study was progression-free survival (PFS), Gonzalez-Martin says. First, patients that tested positive for homologous recombination deficiency (HRD) were analyzed.
Patients who tested positive for HRD demonstrated a median PFS of 21.9 months with niraparib versus 10.4 months with placebo (P<.001). The 24-month overall survival (OS) rate was 91% with niraparib versus 85% with placebo. Based on these positive results, the investigators analyzed the overall population in the study, Gonzalez-Martin says.
In all patients, the median PFS was 13.8 months with niraparib versus 8.2 months with placebo (P<.001). There was a 38% reduction in the risk of progression or death in patients who received niraparib maintenance. The median OS rate in the overall population was 84% with niraparib versus 77% with placebo.
For more information on these data and other findings from PRIMA:https://www.targetedonc.com/conference/esmo-2019/pfs-improved-with-frontline-niraparib-maintenance-in-ovarian-cancer.